Polyphosphazene-Mediated Assembly of TLR4 and TLR7/8 Agonists Enables a Potent Nano-Adjuvant Delivery System for Hepatitis C Virus Vaccine Antigens
Vaccines · 28.09.2025 · 13 (10) · 1012
DOI: 10.3390/vaccines13101012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 28.09.2025. Verfasst von Alexander K Andrianov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
The quest for well-defined immunoadjuvants remains one of the highest priorities for the successful development of effective vaccines. Combination adjuvants, which are designed to integrate both the ability to activate a variety of immune mechanisms and synergistically improve the delivery of vaccine components, are well-positioned to address the unmet needs. The development of a preventive vaccine against hepatitis C virus (HCV)—a major public health concern—is a particular instance in which the choice of the immunoadjuvant is of utmost importance.
Methods
We assembled a lipid A Toll-like receptor 4 (TLR4) agonist BECC438 and TLR7/8 agonist resiquimod (R848) on a polyphosphazene macromolecule (PCPP) to create a nanoscale immunoadjuvant-vaccine delivery system: PCPP-R+BECC438. This aqueous-based system was formulated with the HCV sE2 antigen, and the resulting vaccine candidate was evaluated in vivo for the ability to induce immune responses.
Results
Co-assembly of adjuvants resulted in a visually clear aqueous system of nanoscale dimensions, monomodal size distribution, and entropy-driven interactions between components. Intramuscular immunization of mice with HCV sE2 antigen formulated in a polyphosphazene-based nano-system induced ten-fold higher IgG and IgG2a titers than the antigen adjuvanted with BECC438 alone. PCPP-R+BECC438 formulated HCV sE2 also produced statistically significant improvements in IgG2a/IgG1 ratio and more robust HCVpp neutralization ID50 titers than control formulations.
Conclusions
Polyphosphazene-assembled adjuvant nano-system promotes in vivo immune responses of enhanced quantity and quality of antibodies with increased potency of HCV neutralization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
- Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21021, USA.
- Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.
ORCID-Profile: Alexander K Andrianov, Raman Hlushko, Eric A Toth, Robert K Ernst, Thomas R Fuerst
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Andrianov, A. K., Marin, A., Jeong, S., Kulakova, L., Chowdhury, A., Hlushko, R., Das, S., Moy, F., Toth, E. A., Ernst, R. K., & Fuerst, T. R. (2025). Polyphosphazene-Mediated Assembly of TLR4 and TLR7/8 Agonists Enables a Potent Nano-Adjuvant Delivery System for Hepatitis C Virus Vaccine Antigens. Vaccines, 13(10), 1012. https://doi.org/10.3390/vaccines13101012
Vancouver
Andrianov AK, Marin A, Jeong S, Kulakova L, Chowdhury A, Hlushko R, et al. Polyphosphazene-Mediated Assembly of TLR4 and TLR7/8 Agonists Enables a Potent Nano-Adjuvant Delivery System for Hepatitis C Virus Vaccine Antigens. Vaccines. 2025;13(10):1012. doi:10.3390/vaccines13101012
BibTeX
@article{Andrianov2025,
author = {Andrianov, Alexander K and Marin, Alexander and Jeong, Sarah and Kulakova, Liudmila and Chowdhury, Ananda and Hlushko, Raman and Das, Sayan and Moy, Francesca and Toth, Eric A and Ernst, Robert K and Fuerst, Thomas R},
title = {Polyphosphazene-Mediated Assembly of TLR4 and TLR7/8 Agonists Enables a Potent Nano-Adjuvant Delivery System for Hepatitis C Virus Vaccine Antigens},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {10},
pages = {1012},
doi = {10.3390/vaccines13101012}
}
EUVIMED